On October 20, 2023 SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, reported the presentation of pivotal data from its oncology portfolio at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2023 (Press release, SystImmune, OCT 20, 2023, View Source [SID1234636190]). The event is scheduled to take place from October 20th to 24th in Madrid, Spain, where new clinical findings will be unveiled from trials involving BL-B01D1 and BL-M07D1.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The expanded results from these clinical trials of BL-B01D1 will include data from patients with several solid tumor types in advanced stages and having multiple cycles of prior therapies. The data presented at ESMO (Free ESMO Whitepaper) builds on previously reported clinical data at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), and recent recognition for BL-B01D1 conferred by industry experts at the 14th Annual World ADC meeting in San Diego who recognized SystImmune’s BL-B01D1 as a "Runner-Up" in the award category of "Most Promising Clinical Candidate".
"Encouraging signals of efficacy from the Ed-04 payload supported our decision to expand our pharmacopeia of targeting ADCs that deliver this novel and highly potent topoisomerase 1 inhibitor to a wider patient population with diverse diseases, while we expand our understanding of the exceptional properties of this linker-warhead combination," said Martin Olivo, M.D., CMO of SystImmune.
Presentations at the ESMO (Free ESMO Whitepaper) congress include:
Molecule Name
Title
Abstract Number/
Presentation Details
BL-B01D1
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate,
in patients with non-small cell lung cancer: Updated results from first-
in-human phase I study
Abstract #1316MO
Oral Presentation: Saturday,
October 21st, 9:40 a.m. –
9:45 a.m. CEST
BL-M07D1
BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally
advanced or metastatic HER2 expressing breast cancer and other solid
tumors.
Abstract #2017
Poster Available:
Monday, October 23rd
About BL-B01D1
The company is developing BL-B01D1, a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3. These proteins are highly expressed in most epithelial tumors. The tetravalent BL-B01D1 has two binding domains for distinct Growth Factor Receptors that drive cancer cell proliferation and survival. Inheriting the SI-B001 mechanisms of action, BL-B01D1 blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. Upon antibody mediated internalization, BL-B01D1 is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induced genotoxic stress activating pathways leading to cancer cell death.
About BL-M07D1
The company is developing BL-M07D1, a HER2 specific IgG-based ADC carrying DAR8 of the Ed-04 payload technology. The Ed-04 payload technology is composed of a potent topoisomerase 1 inhibitor and a serum-stable linker that is cleavable by cathepsin-B. By targeting proliferating cancer cells that express HER2, the BL-M07D1 has the potential to treat multiple epithelial cancer types, including breast and colorectal cancer types.